Jagat Chauhan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9197262/publications.pdf

Version: 2024-02-01

11	518	8	11
papers	citations	h-index	g-index
11	11	11	1188
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	TBX3 Promotes Melanoma Migration by Transcriptional Activation of ID1, which Prevents Activation of E-Cadherin by MITF. Journal of Investigative Dermatology, 2021, 141, 2250-2260.e2.	0.7	6
2	TOP1 modulation during melanoma progression and in adaptative resistance to BRAF and MEK inhibitors. Pharmacological Research, 2021, 173, 105911.	7.1	5
3	TBX2 controls a proproliferative gene expression program in melanoma. Genes and Development, 2021, 35, 1657-1677.	5.9	7
4	Lineage-Restricted Regulation of SCD and Fatty Acid Saturation by MITF Controls Melanoma Phenotypic Plasticity. Molecular Cell, 2020, 77, 120-137.e9.	9.7	87
5	<i>ABCB5</i> is activated by MITF and βâ€catenin and is associated with melanoma differentiation. Pigment Cell and Melanoma Research, 2020, 33, 112-118.	3.3	10
6	Paradoxical activation of AMPK by glucose drives selective EP300 activityÂin colorectal cancer. PLoS Biology, 2020, 18, e3000732.	5.6	18
7	E2F1 proteolysis via <scp>SCF</scp> â€cyclin F underlies synthetic lethality between cyclin F loss and Chk1 inhibition. EMBO Journal, 2019, 38, e101443.	7.8	40
8	MITF controls the TCA cycle to modulate the melanoma hypoxia response. Pigment Cell and Melanoma Research, 2019, 32, 792-808.	3.3	41
9	BRN2 suppresses apoptosis, reprograms DNA damage repair, and is associated with a high somatic mutation burden in melanoma. Genes and Development, 2019, 33, 310-332.	5.9	35
10	Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma. Genes and Development, 2017, 31, 18-33.	5.9	184
11	NFIB Mediates BRN2 Driven Melanoma Cell Migration and Invasion Through Regulation of EZH2 and MITF. EBioMedicine, 2017, 16, 63-75.	6.1	85